Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on treating primary and metastatic liver cancers. Its lead product candidate is HEPZATO KIT for administering high-dose chemotherapy to the liver while controlling systemic exposure. The company has a clinical trial program investigating objective response rate in metastatic uveal melanoma.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -91.91%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (2.97%).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- EBITDA Margin (5.08%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 169.7 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 100.0 |